EndoPredict®
Breast Cancer Treatment
Breast cancer is one of the most common cancers in women. With medical advancement these days, most patients can now be treated successfully.
Today we know that in particular the biology of a tumor is crucial for the prognosis of the disease, and that some patients with the correct profile can avoid chemotherapy without jeopardizing the overall treatment success.
What is EndoPredict® Testing?
EndoPredict is a prognostic 2nd generation IVD gene expression test to determine the risk of distant metastases in patients with estrogen receptor positive, HER2-negative primary breast cancer. EndoPredict® is a multi-gene test for breast cancer patients. Using a specially developed procedure, it determines whether a given patient needs chemotherapy, or whether solely anti-hormonal therapy constitutes sufficient treatment.
The test provides additional information to complement the commonly used prognostic factors and is used in particular when based on established information it cannot be clearly decided which treatments are appropriate for you.
EndoPredict® is suitable for the majority of patients with breast cancer, namely for those with a primary, hormone receptor positive, HER2/neu-negative tumor. It is irrelevant whether lymph nodes have already been affected or not.
EndoPredict® allows unambiguous prognostic assessment. The vast majority of patients with hormone receptor-positive and Her2/neu-negative breast cancer have an excellent prognosis – even when the tumour has already infiltrated some lymph nodes. Among these patients EndoPredict® identifies the group which under solely anti-hormonal treatment will in more than 95 % of cases not develop any distant recurrence within ten years. EndoPredict® is thus able to reliably predict even metastasis formation which occurs later than five years after diagnosis.
EndoPredict® test enables personalized treatment decisions. Since tumor cells can be described much more accurately with the EndoPredict® test than conventional prognostic factors allow, therapies can be better targeted. For patients with a low risk of disease progression, this means that they are sufficiently treated with anti-hormonal therapy. Unnecessary chemotherapy can be avoided.
EndoPredict® is the only test of its kind to combine the established clinical prognostic factors of tumor size and lymph node status with the genetic fingerprint of the tumor (EP score) into the EPclin Score. As could be demonstrated in numerous clinical trials, this combination provides valuable additional prognostic information to make an informed treatment decision.
EndoPredict® FAQs
Speak to your doctor. Once your doctor orders a test for you from us, we will take care of the rest. The clinic will take a small blood sample and send it to the lab for testing. The lab cannot accept a test directly from you, as a doctor first needs to assess whether or not the test is right for you. Once the testing is completed, a report will be sent to your doctor who will then go through and explain your results to you, and suggest the next steps.
No! Our processes have been optimized and validated with the kits we provide.
The clinic will help you complete and sign an Informed Consent Form. This form will be submitted with the sample. The consent form will be used to match your sample to the test request submitted by the doctor, and is needed to let the lab know that you have agreed to send your sample for the test. Samples received without these forms cannot be processed, as your consent is required to test your sample.
Myriad will provide your test report to the healthcare professional who ordered the test.
Results are sent to the ordering healthcare professional as they would need to discuss the results, result interpretation, treatment management, and any follow-up testing with you.
